Nonsynonimous mutation of catechol-O-methyl-transferase (COMT) gene in a patient with temporomandibular disorder

Journal of Science and Medicine in Sport

Volumn 13, Issue 6, 2010, Pages 174-179

  D'Antò, Vincenzo ^a   Michelotti, Ambrosina ^a   Esposito, Luciana ^b   Zagari, Adriana ^c   Liguori, Rosario ^c   Sacchetti, Lucia ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

COMT gene; Disc displacement without reduction; Mutation; Pain sensitivity; Temporomandibular joint disorders

Indexed keywords

CATECHOL METHYLTRANSFERASE; GENOMIC DNA; ADENINE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ARGININE; CYTOSINE; SERINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL ASSESSMENT; CRYSTALLOGRAPHY; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; JAW DISEASE; MASTICATORY MUSCLE; MYOFASCIAL PAIN; NOCICEPTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN ASSESSMENT; VISUAL ANALOG SCALE; CODON; DISLOCATION; GENETICS; JOINT CHARACTERISTICS AND FUNCTIONS; MUTATION; PATHOLOGY; PHYSIOLOGY; TEMPOROMANDIBULAR JOINT; TEMPOROMANDIBULAR JOINT DISORDER;

ADENINE; ADULT; ARGININE; CATECHOL O-METHYLTRANSFERASE; CODON; CYTOSINE; DISLOCATIONS; FEMALE; HUMANS; MUTATION; NEUROTRANSMITTER AGENTS; PAIN MEASUREMENT; RANGE OF MOTION, ARTICULAR; SERINE; TEMPOROMANDIBULAR JOINT DISC; TEMPOROMANDIBULAR JOINT DISORDERS; TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME;

EID: 77958451506     PISSN: 14402440     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pio.2010.09.007     Document Type: Article

References (30)

1. Cairns B.E. Pathophysiology of TMD pain - basic mechanisms and their implications for pharmacotherapy. J Oral Rehabil 2010, 37:391-410.
2. Scrivani S.J., Keith D.A., Kaban L.B. Temporomandibular disorders. N Engl J Med 2008, 359:2693-2705.
3. Von Korff M., Le Resche L., Dworkin S.F. First onset of common pain symptoms: a prospective study of depression as a risk factor. Pain 1993, 55:251-258.
4. John M.T., Miglioretti D.L., LeResche L., Von Korff M., Critchlow C.W. Widespread pain as a risk factor for dysfunctional temporomandibular disorder pain. Pain 2003, 102:257-263.
5. Maixner W., Fillingim R., Booker D., Sigurdsson A. Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain. Pain 1995, 63:341-351.
6. Von Korff M.R., Dworkin S.F., Le Resche L., Kriger A. An epidemiologic comparison of pain complaints. Pain 1988, 32:173-183.
7. Dworkin S.F., LeResche L. Research diagnostic criteria for temporomandibular disorders: review, criteria, examinations and specifications, critique. J Craniomandib Disord 1992, 6:301-355.
8. Marbach J.J., Lipton J.A. Treatment of patients with temporomandibular joint and other facial pain by otolaryngologist. Arch Otolaryngol 1982, 108:102-107.
9. Svensson P. Craniofacial muscle pain: review of mechanisms and clinical manifestations. J Orofacial Pain 2001, 15:117-145.
10. DeBoever J.A., Carlsson G.E. Etiology and differential diagnosis. Temporomandibular joint and masticatory muscle disorders 1994, Munksgaard, Copenhagen. G.A. Zarb, G.E. Carlsson, B.J. Sessle, N.D. Mohl (Eds.).
11. Diatchenko L., Nackley A.G., Slade G.D., Fillingim R.B., Maixner W. Idiopathic pain disorders-pathways of vulnerability. Pain 2006, 123:226-230.
12. Nagasako E.M., Oaklander A.L., Dworkin R.H. Congenital insensitivity to pain: an update. Pain 2003, 101:213-219.
13. Slade G.D., Diatchenko L., Ohrbach R., Maixner W. Orthodontic Treatment, Genetic Factors and Risk of Temporomandibular Disorder. Semin Orthod 2008, 14:146-156.
14. Zubieta J.K., Heitzeg M.M., Smith Y.R., Bueller J.A., Xu K., Xu Y., Koeppe R.A., Stohler C.S., Goldman D. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003, 299:1240-1243.
15. Diatchenko L., Slade G.D., Nackley A.G., Bhalang K., Sigurdsson A., Belfer I., Goldman D., Xu K., Shabalina S.A., Shagin D., Max M.B., Makarov S.S., Maixner W. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005, 14:135-143.
16. Melzack R. The McGill Pain Questionnaire: Major properties and scoring methods. Pain 1975, 1:277-299.
17. Rutherford K., Le Trong I., Stenkamp R.E., Parson W.W. Crystal structures of human 108V and 108M catechol O-methyltransferase. J Mol Biol. 2008, 380:120-130.
18. Raphael K.G., Marbach J.J. Widespread pain and the effectiveness of oral splints in myofascial face pain. J Am Dent Assoc 2001, 132:305-316.
19. Vassend O., Krogstad B.S., Dahl B.L. Negative affectivity, somatic complaints, and symptoms of temporomandibular disorders. J Psychosom Res 1995, 39:889-899.
20. Beaton R.D., Egan K.J., Nakagawa-Kogan H., Morrison K.N. Selfreported symptoms of stress with temporomandibular disorders: comparisons to healthy men and women. J Prosthet Dent 1991, 65:289-293.
21. Slade G.D., Diatchenko L., Bhalang K., Sigurdsson A., Fillingim R.B., Belfer I., Max M.B., Goldman D., Maixner W. Influence of psychological factors on risk of temporomandibular disorders. J Dent Res 2007, 86:1120-1125.
22. Piedrafita F.J., Elorriaga C., Fernández-Alvarez E., Nieto O. Inhibition of catechol-O-methyltransferase by N-(3,4-dihydroxyphenyl) maleimide. J Enzyme Inhib 1990, 4:43-50.
23. Pérez R.A., Fernández-Alvarez E., Nieto O., Piedrafita F.J. Kinetics of the reversible tight-binding inhibition of pig liver catechol-O-methyltransferase by [2-(3,4-dihydroxy-2- nitrophenyl)vinyl]phenyl ketone. J Enzyme Inhib 1994, 8:123-131.
24. Bai H.W., Shim J.Y., Yu J., Zhu B.T. Biochemical and molecular modeling studies of the O-methylation of various endogenous and exogenous catechol substrates catalyzed by recombinant human soluble and membrane-bound catechol-O-methyltransferases. Chem Res Toxicol. 2007, 20:1409-1425.
25. Li P.P., Warsh J.J., Godse D.D. Formation and clearance of norepinephrine glycol metabolites in mouse brain. J Neurochem. 1984, 43:1425-1433.
26. Pertovaara A. Noradrenergic pain modulation. Prog Neurobiol 2006, 80:53-83.
27. Wood P.B. Role of central dopamine in pain and analgesia. Expert Rev Neurother 2008, 8:781-797.
28. George S.R., Kertesz M. Met-enkephalin concentrations in striatum respond reciprocally to alterations in dopamine neurotransmission. Peptides. 1987, 8:487-492.
29. Chen J.F., Aloyo V.J., Weiss B. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. Neuroscience. 1993, 54:669-680.
30. Tchivileva I.E., Lim P.F., Smith S.B., Slade G.D., Diatchenko L., McLean S.A., Maixner W. Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenet Genomics 2010, 20:239-248.